NASDAQ
EVGN
Last Price
US $0.48
KEY FIGURES
MKT CAP
$4.2M
EPS
TTM
$-1.21
PEG
TTM
-
P/E
TTM
N/M
P/S
TTM
2.55x
YIELD
0.00%
GROWTH
Revenue Y/Y
Valuation
Financial
Performance
Financial risk - Cash flow debt coverage.
Evogene Ltd. cash flow to debt ratio of -614.29% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Financial stability - Healthy cash flow growth.
Evogene Ltd.'s free cash flow has increased -32.91% from $-20.33M last year to $-13.64M, signaling increasing performance
Financial risk - Healthy debt to equity ratio.
Evogene Ltd.'s debt to equity ratio is -0.80, signaling that the company spent its equity and risk bankruptcy.
Financial risk - Healthy debt to equity ratio development.
Evogene Ltd.'s debt to equity ratio is -0.80, signaling that the company spent its equity and risk bankruptcy.
Financial risk - Net debt/EBITDA.
Evogene Ltd. has negative EBITDA, making leverage ratio unreliable
Financial stability - ICR.
Evogene Ltd. earns at least as much interest as it pays. Interest obligations are fully covered.
Financial risk - Profit margin growth.
Evogene Ltd.'s profit margin has decreased (116.31%) in the last year from -295.59% to -639.39%, signaling decreasing performance
Financial stability - Short term assets vs short term liabilities.
Evogene Ltd.'s short-term assets of $15.63M exceed its short-term liabilities of $3.44M
Decreasing performance - ROA.
Evogene Ltd.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Increasing performance - Absolute return on equity.
Evogene Ltd.'s return on equity of 937.72%, is higher than 15.00%, indicating good performance
Decreasing performance - Earnings quality.
Evogene Ltd.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
Evogene Ltd. had positive net income in only 0.00 out of 5 years, indicating unstable earnings
Decreasing performance - Free cash flow.
Evogene Ltd. has negative free cash flow, indicating the company is burning cash rather than generating it
Decreasing performance - FCF yield.
Evogene Ltd. has negative free cash flow, indicating cash burn
Increasing performance - Healthy earnings growth.
Evogene Ltd.'s yearly earnings has increased -48.53% since last year from $-16.48M to $-8.48M, signaling increasing performance
Decreasing performance - Healthy revenue growth.
Evogene Ltd.'s yearly revenue has decreased -54.73% since last year from $8.51M to $3.85M, signaling decreasing performance
Decreasing performance - ROIC.
ROIC -100.84% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
Increasing performance - 3-year revenue CAGR.
Evogene Ltd.'s 3-year revenue CAGR of 32.01% is positive, indicating growing revenue over the past 3 years
Increasing performance - Revenue consistency.
Evogene Ltd. had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance
Decreasing performance - ROE consistency.
Evogene Ltd. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
Evogene Ltd. has insufficient data to evaluate this check.
Overvalued - Earnings yield.
Evogene Ltd. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - EBITDA valuation.
Evogene Ltd. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
Overvalued - EV/EBITDA.
Evogene Ltd. has negative or missing EBITDA, making EV/EBITDA ratio unreliable
Overvalued - PEG ratio value.
Evogene Ltd. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - P/B ratio.
Evogene Ltd. has negative shareholder equity; price-to-book is not meaningful and the check fails
Undervalued - P/S ratio.
Evogene Ltd. has a price-to-sales ratio of 2.55x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue
Profit margin
Current Ratio
Capital Returns
937.72%
Return on equity
ROIC: -100.84%
Valuation History
-0.34X
Price to Earnings
EV/EBITDA: 0.20X
Cash flow
Profit margin
29.94%
(FY vs FY)
EBITDA Y/Y
13.73%
(FY vs FY)
Cash flow Y/Y
8.17%
(FY vs FY)
Cash Flow (DCF)
Fair Value
Market $0.48
—
Default assumptions
EBITDA Multiple
Fair Value
Market $0.48
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.